The development of antisense oligomer therapeutics for Parkin-type ARJP is still at an early stage, and PD patient dermal fibroblasts have thus far provided a useful model for characterising PRKN mutations and their resulting cumulative cellular damage in patients [33]. The gene discussed is PRKN; the disease is Parkinson disease.